ArticleCancers2021

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436.

Fatih M Uckun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.